Home›Trial›NCT07562087

🔬NCT07562087Phase 2RECRUITING

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

Study Summary

This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.

Conditions

Interventions / Drugs

TP-05 (lotilaner) Low Dose TP-05 (lotilaner) High Dose Placebo

View on ClinicalTrials.gov ↗

Sponsor

Tarsus Pharmaceuticals, Inc.

Biotech / Pharma

Study Details

Enrollment700 participants

Primary Completion—

Lead SponsorTarsus Pharmaceuticals, Inc.

Data Retrieved2026-06-17 02:58:25.715387+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.